United States Patient Preference and Usability for the New Disposable Insulin Device Solostar® versus Other Disposable Pens

Jerome S. Fischer, M.D.,1 Steven V. Edelman, M.D.,2 and Sherwyn L. Schwartz, M.D., P.A.1

Abstract

The uptake of insulin pen use has been slow in the United States, despite their advantages over the vial/syringe. We present results of a United States subset of 150 patients with type 1/type 2 diabetes, who were enrolled in an open-label study, that assessed usability, pen features, and patient preferences for four prefilled insulin pens: SoloSTAR®, FlexPen®, Lilly disposable pen, and a prototype, Pen X. Overall, the SoloSTAR and FlexPen were more user-friendly; 95% and 88% of patients, respectively, completed the steps correctly (without safety/attach-needle step—deemed independent of device) versus the Lilly disposable pen (60%) and Pen X (61%; all \( p < 0.05 \)). The SoloSTAR was rated highest most frequently for pen feature comparisons. Results suggest that the SoloSTAR and FlexPen could potentially facilitate insulin use in the United States.


Author Affiliations: 1Diabetes and Glandular Disease Research Associates, Inc., San Antonio, Texas, and 2University of California, San Diego Veterans Affairs Medical Center, San Diego, California

Abbreviations: (OAD) oral antidiabetic drug, (SD) standard deviation, (T1DM) type 1 diabetes mellitus, (T2DM) type 2 diabetes mellitus

Keywords: disposable pen, FlexPen, insulin device, Lilly disposable pen, SoloSTAR, United States

Corresponding Author: Sherywn L. Schwartz, M.D., P.A., Diabetes and Glandular Disease Research Associates, Inc., 5107 Medical Drive, San Antonio, TX 78229-4801; email address slschwartz@dgdclinic.com